Details
Stereochemistry | ACHIRAL |
Molecular Formula | 2C5H7O2.Cu |
Molecular Weight | 261.762 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cu++].CC(=O)[CH-]C(C)=O.CC(=O)[CH-]C(C)=O
InChI
InChIKey=KMOVDRADWUSGIH-UHFFFAOYSA-N
InChI=1S/2C5H7O2.Cu/c2*1-4(6)3-5(2)7;/h2*3H,1-2H3;/q2*-1;+2
Molecular Formula | C5H8O2 |
Molecular Weight | 100.1158 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Cu |
Molecular Weight | 63.546 |
Charge | 2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/23413123Curator's Comment: description was created based on several sources, including:
http://repositorio.unicamp.br/bitstream/REPOSIP/93476/1/2-s2.0-27844469706.pdf | DOI: 10.1002/047084289X.rc204.pub2
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23413123
Curator's Comment: description was created based on several sources, including:
http://repositorio.unicamp.br/bitstream/REPOSIP/93476/1/2-s2.0-27844469706.pdf | DOI: 10.1002/047084289X.rc204.pub2
COPPER(II) 4-OXOPENT-2-EN-2-OLATE (Copper(II) acetylacetonate [Cu(acac)2]) is a soluble copper catalyst that has been widely employed in many types of reactions. It is a powerful reagent in organic synthesis. Anticancer properties of Copper(II) acetylacetonate complex was found by treating different cancer cell lines. The TUNEL assay showed a strong positivity in the C6 cells treated with Cu(acac)2 and this indicates that the Cu compounds initiated cell death by DNA fragmentation.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2311221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23413123 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23413123
Low doses of Copper(II) acetylacetonate alone were necessary to kill approximately 90% of cells of different cancer cell lines (C6, RG2, B16, and U373) (∼62.5 mg/mL).
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:58:01 GMT 2023
by
admin
on
Sat Dec 16 08:58:01 GMT 2023
|
Record UNII |
69QQY9TJ8M
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
13395-16-9
Created by
admin on Sat Dec 16 08:58:01 GMT 2023 , Edited by admin on Sat Dec 16 08:58:01 GMT 2023
|
PRIMARY | |||
|
DTXSID50904281
Created by
admin on Sat Dec 16 08:58:01 GMT 2023 , Edited by admin on Sat Dec 16 08:58:01 GMT 2023
|
PRIMARY | |||
|
Copper(II) acetylacetonate
Created by
admin on Sat Dec 16 08:58:01 GMT 2023 , Edited by admin on Sat Dec 16 08:58:01 GMT 2023
|
PRIMARY | |||
|
256
Created by
admin on Sat Dec 16 08:58:01 GMT 2023 , Edited by admin on Sat Dec 16 08:58:01 GMT 2023
|
PRIMARY | |||
|
236-477-9
Created by
admin on Sat Dec 16 08:58:01 GMT 2023 , Edited by admin on Sat Dec 16 08:58:01 GMT 2023
|
PRIMARY | |||
|
2723615
Created by
admin on Sat Dec 16 08:58:01 GMT 2023 , Edited by admin on Sat Dec 16 08:58:01 GMT 2023
|
PRIMARY | |||
|
69QQY9TJ8M
Created by
admin on Sat Dec 16 08:58:01 GMT 2023 , Edited by admin on Sat Dec 16 08:58:01 GMT 2023
|
PRIMARY |